新京报讯（记者王卡拉）在第八届中国国际进口博览会（以下简称"进博会"）上，多位风湿免疫领域资 深专家、学者、公益组织伙伴齐聚葛兰素史克（GSK）展区，共同围绕系统性红斑狼疮（SLE）的疾病 认知、患者支持与慢病管理等议题展开交流，旨在提升公众科学认知、改善患者生存环境，助力患者重 拾生活信心。 上海交通大学医学院附属瑞金医院肾内科终身教授陈楠表示，患者在确诊狼疮肾炎后，应尽早规范治疗 和长期持续监测病情（动态监测尿蛋白、尿沉渣和肾功能等），结合必要的疾病活动度、肾活检、生物 标志物等指标综合评估疗效，同时需要做好疾病自我管理。 记录狼疮患者真实生活的"陪她，寻回美好生活"公益短片同期发布，该短片讲述了一位女性狼疮患者从 确诊之初的迷茫无措，到学会与"狼"共舞、成功孕育新生命，最终经过规范治疗重拾美好生活的全过 程。 校对 付春愔 系统性红斑狼疮是一种慢性自身免疫性结缔组织疾病，可导致肾脏、心血管、肺、消化系统、血液系 统、眼部等多器官、组织的损伤，并显著增高患者的死亡风险。目前，中国狼疮患者已超100万，多见 于育龄女性。随着我国近年来狼疮诊治水平不断提高，狼疮患者的生存率得到显著改善。面对逐渐慢病 化的系统 ...

Core Viewpoint - GSK successfully hosted discussions at the China International Import Expo (CIIE) focusing on systemic lupus erythematosus (SLE), aiming to enhance public awareness and improve patient support and chronic disease management [1][2][3] Group 1: Disease Overview - Systemic lupus erythematosus is a chronic autoimmune connective tissue disease that can damage multiple organs, significantly increasing patient mortality risk [3] - There are over 1 million lupus patients in China, predominantly among women of childbearing age, with improved survival rates due to advancements in diagnosis and treatment [3] Group 2: GSK's Commitment - GSK has been a dedicated partner of the CIIE, leveraging its influence to accelerate the accessibility of innovative drugs and extend support to patients in need [3] - GSK has been focused on the lupus field for over a decade, with its drug Benlysta (belimumab) expanding its indications to meet the needs of Chinese patients [3] Group 3: Patient Management and Treatment - Experts emphasize the importance of early diagnosis and treatment for children with lupus, highlighting the value of biologics like Benlysta in managing the disease effectively [5] - Continuous monitoring and standardized treatment are crucial for patients diagnosed with lupus nephritis to prevent complications and protect kidney function [6][7] Group 4: Collaborative Efforts - GSK is actively collaborating with various organizations to establish a standardized national lupus treatment system, aiming to improve patient outcomes [7] - Since signing a strategic cooperation memorandum with GSK, significant progress has been made in disease education and patient care, with expectations for further collaboration to enhance the quality of life for lupus patients in China [7]

Core Viewpoint - The recent departure of Cecilia Qi from GSK has raised attention, marking a significant leadership change within the company in China as she transitions to become the CEO of DCH Auriga after a 25-year career in the global pharmaceutical industry [1][3]. Group 1: Leadership Change - Cecilia Qi announced her departure from GSK on September 1, 2023, to take on the role of CEO at DCH Auriga, a comprehensive healthcare marketing management service provider based in Asia [3][6]. - Qi has been with GSK for over 20 years, having joined the company in 2004, and was the first local general manager of GSK China [6][7]. - Following Qi's departure, GSK has not yet provided information regarding her successor or any potential business restructuring plans [6]. Group 2: GSK's Strategic Goals - Under Qi's leadership, GSK China received increased attention from the global headquarters, with several key products approved for the Chinese market, including vaccines and treatments for various diseases [7][8]. - GSK aims to become one of the top ten multinational pharmaceutical companies in China by 2030, with plans to surpass Japan and establish China as GSK's second-largest market globally by 2031 [8][9]. - The company anticipates over 20 new products or indications to be approved in China within the next five years [8]. Group 3: Industry Context - The pharmaceutical industry in China has seen multiple leadership changes among multinational companies, including AstraZeneca, Merck, Novartis, and Takeda, indicating a trend of executive turnover in the sector [9].